참고문헌
- Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A and Delbono O (2015) Pericytes at the intersection between tissue regeneration and pathology. Clin Sci (Lond) 128, 81-93 https://doi.org/10.1042/CS20140278
- Birbrair A, Zhang T, Wang ZM et al (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 307, C25-38 https://doi.org/10.1152/ajpcell.00084.2014
- Alitalo K and Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227 https://doi.org/10.1016/S1535-6108(02)00051-X
- Davis S, Aldrich TH, Jones PF et al (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169 https://doi.org/10.1016/S0092-8674(00)81812-7
- Ferrara N and Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18, 4-25 https://doi.org/10.1210/edrv.18.1.0287
- Heldin CH and Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79, 1283-1316 https://doi.org/10.1152/physrev.1999.79.4.1283
- Shibuya M, Ito N and Claesson-Welsh L (1999) Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 237, 59-83
- Wang HU, Chen ZF and Anderson DJ (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741-753 https://doi.org/10.1016/S0092-8674(00)81436-1
- Smith GA, Fearnley GW, Harrison MA, Tomlinson DC, Wheatcroft SB and Ponnambalam S (2015) Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. J Inherit Metab Dis 38, 753-763 https://doi.org/10.1007/s10545-015-9838-4
- Carmeliet P and Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 https://doi.org/10.1038/nature10144
- Shibuya M (2013) Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153, 13-19 https://doi.org/10.1093/jb/mvs136
- Cross MJ, Dixelius J, Matsumoto T and Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28, 488-494 https://doi.org/10.1016/S0968-0004(03)00193-2
- Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47 https://doi.org/10.1038/nrc704
- Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G and Aprile G (2014) Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2, 123
- de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 https://doi.org/10.1126/science.1312256
- Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL and Shows TB (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677-1683
- Shibuya M and Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312, 549-560 https://doi.org/10.1016/j.yexcr.2005.11.012
- Shibuya M (2011) Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc Jpn Acad Ser B Phys Biol Sci 87, 167-178 https://doi.org/10.2183/pjab.87.167
- Iyer S, Darley PI and Acharya KR (2010) Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity. J Biol Chem 285, 23779-23789 https://doi.org/10.1074/jbc.M110.130658
- Davis-Smyth T, Chen H, Park J, Presta LG and Ferrara N (1996) The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 15, 4919-4927
- Tanaka K, Yamaguchi S, Sawano A and Shibuya M (1997) Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res 88, 867-876 https://doi.org/10.1111/j.1349-7006.1997.tb00463.x
- Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M and Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269, 26988-26995
- Roskoski R Jr (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375, 287-291 https://doi.org/10.1016/j.bbrc.2008.07.121
- Autiero M, Waltenberger J, Communi D et al (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9, 936-943 https://doi.org/10.1038/nm884
- Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62, 179-213 https://doi.org/10.1016/j.critrevonc.2007.01.006
- Brozzo MS, Bjelic S, Kisko K et al (2012) Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood 119, 1781-1788 https://doi.org/10.1182/blood-2011-11-390922
- Leppanen VM, Tvorogov D, Kisko K et al (2013) Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc Natl Acad Sci U S A 110, 12960-12965 https://doi.org/10.1073/pnas.1301415110
- Ruch C, Skiniotis G, Steinmetz MO, Walz T and Ballmer-Hofer K (2007) Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol 14, 249-250 https://doi.org/10.1038/nsmb1202
- Yang Y, Xie P, Opatowsky Y and Schlessinger J (2010) Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proc Natl Acad Sci U S A 107, 1906-1911 https://doi.org/10.1073/pnas.0914052107
- Markovic-Mueller S, Stuttfeld E, Asthana M et al (2017) Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A. Structure 25, 341-352 https://doi.org/10.1016/j.str.2016.12.012
- Christinger HW, Fuh G, de Vos AM and Wiesmann C (2004) The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem 279, 10382-10388 https://doi.org/10.1074/jbc.M313237200
- Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA and de Vos AM (1997) Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695-704 https://doi.org/10.1016/S0092-8674(00)80456-0
- McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J and Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A 109, 18281-18289 https://doi.org/10.1073/pnas.1207759109
- McTigue MA, Wickersham JA, Pinko C et al (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7, 319-330 https://doi.org/10.1016/S0969-2126(99)80042-2
- Okamoto K, Ikemori-Kawada M, Jestel A et al (2015) Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett 6, 89-94 https://doi.org/10.1021/ml500394m
- Oguro Y, Miyamoto N, Okada K et al (2010) Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5Hpyrrolo[ 3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem 18, 7260-7273 https://doi.org/10.1016/j.bmc.2010.08.017
- Fong GH, Rossant J, Gertsenstein M and Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 https://doi.org/10.1038/376066a0
- Hiratsuka S, Minowa O, Kuno J, Noda T and Shibuya M (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 95, 9349-9354 https://doi.org/10.1073/pnas.95.16.9349
- Landgren E, Schiller P, Cao Y and Claesson-Welsh L (1998) Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16, 359-367 https://doi.org/10.1038/sj.onc.1201545
- Sawano A, Takahashi T, Yamaguchi S and Shibuya M (1997) The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma. Biochem Biophys Res Commun 238, 487-491 https://doi.org/10.1006/bbrc.1997.7327
- Cunningham SA, Waxham MN, Arrate PM and Brock TA (1995) Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 270, 20254-20257 https://doi.org/10.1074/jbc.270.35.20254
- Katoh O, Tauchi H, Kawaishi K, Kimura A and Satow Y (1995) Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55, 5687-5692
- Shalaby F, Rossant J, Yamaguchi TP et al (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66 https://doi.org/10.1038/376062a0
- Holmqvist K, Cross MJ, Rolny C et al (2004) The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279, 22267-22275 https://doi.org/10.1074/jbc.M312729200
- Matsumoto T, Bohman S, Dixelius J et al (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24, 2342-2353 https://doi.org/10.1038/sj.emboj.7600709
- Karkkainen MJ, Haiko P, Sainio K et al (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5, 74-80 https://doi.org/10.1038/ni1013
- Makinen T, Veikkola T, Mustjoki S et al (2001) Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20, 4762-4773 https://doi.org/10.1093/emboj/20.17.4762
- Dixelius J, Makinen T, Wirzenius M et al (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278, 40973-40979 https://doi.org/10.1074/jbc.M304499200
- Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674 https://doi.org/10.1016/j.cell.2011.02.013
- Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186 https://doi.org/10.1056/NEJM197111182852108
- Carmeliet P, Moons L, Luttun A et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7, 575-583 https://doi.org/10.1038/87904
- Hattori K, Heissig B, Wu Y et al (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8, 841-849 https://doi.org/10.1038/nm740
- Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111, 649-658 https://doi.org/10.1172/JCI17189
- Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K and Vikkula M (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67, 295-301 https://doi.org/10.1086/303019
- Rockson SG (2001) Lymphedema. Am J Med 110, 288-295 https://doi.org/10.1016/S0002-9343(00)00727-0
- Gerber HP and Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65, 671-680
- Quesada AR, Munoz-Chapuli R and Medina MA (2006) Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26, 483-530 https://doi.org/10.1002/med.20059
- Piao Y, Henry V, Tiao N et al (2017) Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget 8, 96970-96983
- Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24, 16-24 https://doi.org/10.1200/JCO.2005.02.2574
- Chen X, Zheng Z, Chen L and Zheng H (2017) MAPK, NFkappaB, and VEGF signaling pathways regulate breast cancer liver metastasis. Oncotarget 8, 101452-101460
- Chen Y, Liu Y, Wang Y et al (2017) Quantification of STAT3 and VEGF expression for molecular diagnosis of lymph node metastasis in breast cancer. Medicine (Baltimore) 96, e8488 https://doi.org/10.1097/MD.0000000000008488
- Schirosi L, De Summa S, Tommasi S et al (2017) VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients. Int J Cancer 141, 1901-1911 https://doi.org/10.1002/ijc.30868
피인용 문헌
- Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor pp.1724-6016, 2019, https://doi.org/10.1177/1120672119832785